Key features and details
- Mouse monoclonal [DR-4-02] to DR4 (FITC)
- Suitable for: IP, Functional Studies, Flow Cyt
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
Product nameAnti-DR4 antibody [DR-4-02] (FITC)
See all DR4 primary antibodies
DescriptionMouse monoclonal [DR-4-02] to DR4 (FITC)
ConjugationFITC. Ex: 493nm, Em: 528nm
SpecificityThe antibody recognizes TRAIL R1 (DR4), a human death receptor 4 (468 amino acids) expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) and in a variety of tumour derived cell lines.
Tested applicationsSuitable for: IP, Functional Studies, Flow Cytmore details
Species reactivityReacts with: Human
Fusion protein (Human) containing the extracellular part of DR4 and the constant part of the heavy chain of human IgG1.
General notesDo not use after expiration date stamped on vial label. Short term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.
Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.
The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferPreservative: 0.097% Sodium azide
Constituent: 0.2% BSA
0.2% high grade protease free BSA
Concentration information loading...
Purification notesThe antibody was >95% pure prior to conjugation as determined from SDS-PAGE (by protein A affinity chromatography).
Primary antibody notesSoluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.
Our Abpromise guarantee covers the use of ab59047 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.|
|Functional Studies||Use a concentration of 2 - 3 µg/ml. in cultivation medium. Final concentration of TRAIL: 20-200 ng/ml. Note: It is recommended that the antibody is added 15 min before the addition of TRAIL.|
|Flow Cyt||Use a concentration of 5 µg/ml.
ab91356 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
FunctionReceptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B.
Tissue specificityWidely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K562 erythroleukemia cells, MCF7 breast carcinoma cells and activated T-cells.
Sequence similaritiesContains 1 death domain.
Contains 3 TNFR-Cys repeats.
- Information by UniProt
- Apo2 antibody
- CD261 antibody
- Cytotoxic TRAIL receptor antibody
ab59047 has been referenced in 4 publications.
- Strekalova E et al. Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction. Methods Mol Biol 1866:61-73 (2019). PubMed: 30725408
- Piggott L et al. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clin Cancer Res 24:2452-2463 (2018). PubMed: 29363524
- Nesterenko I et al. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. PLoS One 7:e49219 (2012). Flow Cyt ; Human . PubMed: 23145127
- Fan S et al. Scatter factor protects tumor cells against apoptosis caused by TRAIL. Anticancer Drugs 21:10-24 (2010). IP . PubMed: 19823077